efocipegtrutide

Efocipegtrutide (HM15275) is a novel, long-acting triple agonist peptide that targets the glucagon-like peptide-1 receptor (GLP-1R), gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR). It is rationally designed to provide optimized, balanced activation of these three incretin and metabolic hormone pathways for the treatment of obesity and related metabolic disorders. The drug aims to maximize body weight reduction by combining both food intake inhibition and increased energy expenditure, with preclinical studies demonstrating superior weight loss compared to semaglutide or tirzepatide. Efocipegtrutide also shows favorable glycemic control effects and potential benefits in improving cardiovascular and kidney function. Developed by Hanmi Pharmaceutical, it is currently in Phase 1 clinical trials for obesity[1][2][3][5][6][7].

Brand names

HM15211HM-15211HM 15211

Other names

HM15275HM-15275HM 15275efocipegtrutide